A more meaningful scoring system for determining the severity of coronary heart disease

Author(s): Gensini GG

Abstract

Objective Most current cardiovascular disease (CVD) risk stratification tools are for people without CVD, but very few are for prevalent CVD. In this study, we developed and validated a CVD severity score in people with coronary heart disease (CHD) and evaluated the association between severity and adverse outcomes.

Methods Primary and secondary care data for 213 088 people with CHD in 398 practices in England between 2007 and 2017 were used. The cohort was randomly divided into training and validation datasets (80%/20%) for the severity model. Using 20 clinical severity indicators (each assigned a weight=1), baseline and longitudinal CVD severity scores were calculated as the sum of indicators. Adjusted Cox and competing-risk regression models were used to estimate risks for all-cause and cause-specific hospitalisation and mortality.

Results Mean age was 64.5±12.7 years, 46% women, 16% from deprived areas, baseline severity score 1.5±1.2, with higher scores indicating a higher burden of disease. In the training dataset, 138 510 (81%) patients were hospitalised at least once, and 39 944 (23%) patients died. Each 1-unit increase in baseline severity was associated with 41% (95% CI 37% to 45%, area under the receiver operating characteristics (AUROC) curve=0.79) risk for 1 year for all-cause mortality; 59% (95% CI 52% to 67%, AUROC=0.80) for cardiovascular (CV)/diabetes mortality; 27% (95% CI 26% to 28%) for any-cause hospitalisation and 37% (95% CI 36% to 38%) for CV/diabetes hospitalisation. Findings were consistent in the validation dataset.

Similar Articles

Global Atlas on Cardiovascular Disease Prevention and Control.

Author(s): Mendis S, Puska P, Norrving B

Pathogenesis of Acute Coronary Syndromes

Author(s): Crea F, Liuzzo G

Mechanisms of Plaque Formation and Rupture

Author(s): Bentzon JF, Otsuka F, Virmani R, Falk E

Matrix Metalloproteinase-9?: Many Shades of Function in Cardiovascular Disease.

Author(s): Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML

Association of serum MMP-9 with autoantibodies against oxidized LDL

Author(s): Kalela A, Koivu TA, Höyhtyä M, Jaakkola O, Lehtimäki T

2013 ESC guidelines on the management of stable coronary artery disease: Eur Heart

Author(s): Montalescot G, Sechtem U, Achenbach S, Andreotti F

Chronic Stable Angina.

Author(s): Abrams J

The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.

Author(s): Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A

The oxidation ratio of LDL: a predictor for coronary artery disease.

Author(s): Huang H, Mai W, Liu D, Hao Y, Tao J

Antibodies against oxLDL and acute coronary syndrome.

Author(s): Medeiros AM, von Mühlen CA, Gidlund MA, Bodanese R, Gottlieb MG

Plaque regression and plaque stabilisation in cardiovascular diseases.

Author(s): Dave T, Ezhilan J, Vasnawala H, Somani V

Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease

Author(s): Kalela A, Koivu TA, Sisto T, Kanervisto J, Höyhtyä M